NiaHealth Taps ex-HelloFresh Exec as First Chief Marketing Officer and Announces Product Expansion as Company Enters Hyper-Growth Phase
TORONTO, July 31, 2025 /CNW/ - NiaHealth, Canada's fastest-growing consumer proactive health company, today announced the appointment of Candy Lee as its first Chief Marketing Officer, marking a major milestone in the company's evolution from emerging startup to national category leader. The announcement today also includes significant product expansion as part of NiaHealth's mission to become Canada's most powerful and comprehensive proactive health platform—launching Continuous Glucose Monitoring (CGM) out of beta, tripling the size of its clinician team, and expanding its core testing panel from 50+ to over 150 biomarkers, now the most complete longevity and healthspan assessment available to Canadians.
This news follows a string of major milestones for NiaHealth, including its public debut out of stealth in April, national platform enhancements announced live at Web Summit in May, and the closing of a $5.75M seed fundraise in June led by Golden Ventures, Version One, and other top-tier Canadian tech investors.
"Momentum is real, and it's accelerating," said Sameer Dhar, CEO and Co-Founder of NiaHealth. "We've gone from stealth to scale in just a few months—but we've stayed grounded in our mission. Every new test, every clinical consult, every continuous glucose monitor scan is about helping Canadians feel better and live longer. Candy's appointment is a massive leap forward—she's built some of the most loved brands in Canada, and she understands how to meet people where they are. We're not just innovating—we're making proactive care truly accessible."
Lee's career spans award-winning marketing and growth leadership at HelloFresh, Homebase, ecobee, and Budweiser—Canada's #1 beer—earning recognition from the Cannes Lions, FastCompany, CMA Awards, Media Innovation Awards, and more. But it was a personal health reckoning that brought her to NiaHealth.
"A decade ago, I hit a turning point in my own health," said Candy Lee, Chief Marketing Officer at NiaHealth. "What looked fine on paper spiralled into months of fatigue, inflammation, and unanswered questions. Through that journey, I learned that with the right clinical guidance and proactive biomarker testing, so much of that suffering could have been avoided. What excites me most about NiaHealth isn't just the science or the product—it's the humanity. This is a company that leads with empathy, with clinicians guiding every step. And the opportunity to bring that to millions of Canadians? That's the kind of mission you drop everything for."
NiaHealth's platform now includes access to 150+ evidence-backed biomarkers, one-on-one consultations with longevity-trained clinicians, and advanced data integrations with gut microbiome test insights, Vo2Max, DEXA Body Scans, CGMs and fitness wearables like Oura Ring, Fitbit, and Garmin. By combining long-range biomarkers with real-time health data, members gain a full-circle view of their health—before symptoms ever begin.
The company has completed nearly 150,000 biomarker tests across the country, with over 90% of members discovering at least one previously unknown—but actionable—health risk, such as pre-diabetes, vitamin D deficiency, or early heart disease indicators. NiaHealth operates in every province except Quebec and offers HSA-eligible plans starting at $299/year.
Designed to complement Canada's public healthcare system, NiaHealth supports Canadians between doctor visits—focusing on long-term prevention, lifestyle change, and early intervention.
"This next chapter isn't just about scale—it's about impact for Canadians," said Dhar. "We're proving that proactive health can be evidence-based, clinician-guided, and built for real life. That's the future we're working toward, and we're just getting started."
About NiaHealth
NiaHealth is Canada's leading proactive health platform, helping people live longer, healthier lives through advanced biomarker testing, personalized clinical guidance, and real-time tools like continuous glucose monitoring and fitness wearable integration. With nearly 150,000 biomarker tests completed and plans starting at $299/year, NiaHealth is proudly built in Canada, for Canadians—designed to empower members with long-range insights, early risk detection, and actionable support. Learn more at niahealth.co.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
14 minutes ago
- Cision Canada
Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada, Aug. 6, 2025 /CNW/ -- ESSA Pharma Inc. (" ESSA," or the " Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the " Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the " Common Shares" and the holders of such Common Shares, the " Shareholders") and concurrent distribution to the Shareholders, the board of directors of the Company (the " Board") has approved a return of capital distribution in the aggregate amount of US$80,000,000 (the " Distribution") to the Shareholders as part of the discontinuance and winding-up of the business of the Company. The Distribution is scheduled to be paid on August 22, 2025, to Shareholders of record as of the close of business on August 19, 2025. The Distribution will occur prior to the special meeting of the Company's Shareholders, optionholders and warrantholders that is being held to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. (" Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the " Transaction"), which meeting is expected to be held on September 10, 2025 (the " Special Meeting"). On August 5, 2025, the Company obtained an interim order from the Court authorizing the Special Meeting. In total, with the Distribution and the cash payable upon closing of the Transaction, each Shareholder is currently estimated to receive approximately US$1.91 per Common Share, exclusive of any contingent value rights payments Shareholders are entitled to receive pursuant to the Transaction. About ESSA Pharma Inc. ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit Forward Looking Statement This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements"). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, the amounts payable under the Transaction; the Company's application to the Supreme Court of British Columbia for a reduction of capital and cash distribution prior to the closing of the Transaction; the timing and receipt of securityholder, regulatory and court approvals of the Transaction; the satisfaction of the conditions to the completion of the Transaction and other statements that are not statements of historical facts. In this communication, these forward-looking statements are based on ESSA's current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by ESSA, all of which are subject to change. Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, regulatory, political and social uncertainties and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited to (i) the completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory and court approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) the potential for the date of the Special Meeting to change; (iii) potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto; (iv) the risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations; (v) the ability of ESSA to retain and hire key personnel; (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; (vii) continued availability of capital and financing and rating agency actions; (viii) legislative, regulatory and economic developments affecting ESSA's business; (ix) the accuracy of ESSA's financial projections; (x) general business, market and economic conditions; (xi) certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions; (xii) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as ESSA's response to any of the aforementioned factors; (xiii) significant transaction costs associated with the Transaction; (xiv) the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xv) competitive responses to the Transaction; (xvi) the risks and uncertainties pertaining to ESSA's business, including those set forth in ESSA's Annual Report on Form 10-K dated December 17, 2024, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at and on SEDAR+ at and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles; and (xvii) the risks and uncertainties that will be described in the proxy statement and management information circular for the Company's securityholders filed with the U.S. Securities and Exchange Commission (the " SEC," and such statement, the " Proxy Statement") available from the sources indicated above. These risks, as well as other risks associated with the Transaction, will be more fully discussed in the Proxy Statement. While the list of factors presented here is, and the list of factors to be presented in the Proxy Statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on ESSA's financial condition, results of operations, credit rating or liquidity. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements. Important Additional Information and Where to Find It In connection with the proposed Transaction between ESSA, Xeno and XOMA Royalty Corporation, ESSA has filed with the SEC the preliminary Proxy Statement on July 31, 2025, the definitive version of which will be filed with the SEC and sent or provided to ESSA securityholders. ESSA may also file other documents with the SEC regarding the proposed Transaction. This document is not a substitute for the Proxy Statement or any other document which ESSA may file with the SEC or send or provide to ESSA securityholders in connection with the Transaction. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and securityholders may obtain free copies of the Proxy Statement and other documents that are filed or will be filed with the SEC by ESSA (when they become available) through the website maintained by the SEC at on SEDAR+ at or at ESSA's website at Participants in the Solicitation ESSA and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from ESSA's shareholders in connection with the proposed Transaction. Additional information regarding such participants, including a description of their direct or indirect interests, by security holdings or otherwise, can be found under the captions "THE ARRANGEMENT – Interests of the Company's Directors and Executive Officers in the Arrangement", "IMPORTANT INFORMATION ABOUT THE COMPANY – Security Ownership" and "INTERESTS OF THE COMPANY'S DIRECTORS AND EXECUTIVE OFFICERS IN THE ARRANGEMENT" contained in the preliminary Proxy Statement filed with the SEC on July 31, 2025. Information relating to the foregoing can also be found in ESSA's proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on January 22, 2025 (the " Annual Meeting Proxy Statement"). To the extent holdings of securities by potential participants changed since the applicable "as of" date disclosed in the preliminary Proxy Statement, such information has been or will be reflected on ESSA's Statements of Change in Ownership on Forms 3 and 4 filed with the SEC. You may obtain free copies of these documents using the sources indicated above. or / Dan Moore [email protected] SOURCE ESSA Pharma Inc.
Cision Canada
14 minutes ago
- Cision Canada
CANTEX ANNOUNCES CLOSING OF FIRST TRANCHE OF A NON-BROKERED PRIVATE PLACEMENT
KELOWNA, BC, Aug. 6, 2025 /CNW/ - Cantex Mine Development Corp. (TSXV: CD) (OTCQB: CTXDF) (the " Company") is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement (the " Offering"). The first tranche of the Offering consisted of 4,839,999 charity flow through units (" CFT Units") at $0.21 per CFT Unit and 5,731,372 hard units (" Units") at $0.14 per Unit for total gross proceeds of $1,818,791.87. Each CFT Unit is comprised of one flow through share and one non-flow through warrant. Each Unit is comprised of one common share and one non-flow through warrant. Each whole warrant issued in connection with the Offering entitles the holder to acquire one common share at a price of $0.21 for a term of three years. 0974052 B.C. Ltd. (" BC Ltd"), a company over which Dr. Charles Fipke, the Chairman and a control person of the Company exercises control and direction over, subscribed for 3,571,429 Units for a total subscription price of $500,000. The issuance of the Units to BC Ltd. constitutes a "related party transaction" as defined in Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions (" MI 61-101"). The Company is relying on the exemption from valuation requirements and minority approval pursuant to subsections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, for the Insider participation in the Offering, as the value of the Units subscribed for does not represent more than 25% of the Company's market capitalization, as determined in accordance with MI 61-101. In connection with the closing of the first tranche of the Offering, the Company paid an aggregate cash finders' fee of $36,652 and issued an aggregate of 391,692 non-transferable finders' warrants (the " Finder's Warrants") to certain arm's length finders. Each Finder's Warrant entitles the holder to purchase one common share (a " Finder Share") at an exercise price of $0.21 per Finder Share for a period of three years from the date of issuance of the Finder's Warrant. Proceeds from the Offering will be used to fund qualified critical mineral exploration expenditures on the Company's North Rackla project in the Yukon and for general operations. The Offering remains subject to the acceptance of the TSX Venture Exchange. About Cantex Cantex is focused on its 100% owned 20,000 hectare North Rackla Project located 150 kilometers northeast of the town of Mayo in the Yukon Territory, Canada where high-grade massive sulphide mineralization has been discovered. Over 60,000 meters of drilling has defined high grade silver-lead-zinc-germanium mineralization over 2.3 kilometers of strike length and 700 meters depth. The mineralization remains open along strike and to depth. The Company is led by Dr. Charles Fipke, C.M., the founder of Ekati, Canada's first diamond mine. The technical information and results reported here have been reviewed by Mr. Chad Ulansky a Qualified Person under National Instrument 43-101, who is responsible for the technical content of this release. Signed, Chad Ulansky Chad Ulansky President and CEO Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Cantex Mine Development Corp.
Cision Canada
14 minutes ago
- Cision Canada
GTAA REPORTS 2025 SECOND QUARTER RESULTS
TORONTO, Aug. 6, 2025 /CNW/ - The Greater Toronto Airports Authority ("GTAA") today reported its financial and operating results for the second quarter and the first half of 2025. Toronto Pearson, Canada's busiest airport, saw slight growth in its overall passenger volumes, which increased by 0.3 million or 1.5% to 12.0 million for the second quarter and 0.1 million or 0.1% to 22.7 million year-to-date, when compared to the same periods of 2024. This was largely driven by strong growth in both the domestic and international sectors. Overall international growth was offset by a decline in transborder travel. Year-to-date passenger volume was also impacted by extreme weather events, and a five-day runway closure due to a single aircraft incident in the first quarter. "Q2 2025 was encouraging with growth in domestic and international sectors, which offset the decline in transborder U.S. travel. Amid ongoing uncertainties in the global economic and political landscape, year-to-date performance is as strong as 2024, and our long-term strategy remains firmly on track," said Deborah Flint, President and CEO. "We continue to meet milestones in our infrastructure plans," added Ms. Flint. "Pearson is a national economic driver, and we remain focused on increasing our connectivity as a global hub airport that strengthens Canada's economy." Toronto Pearson continues to monitor the global economic and political landscape closely, assessing risks and ready to adapt in economic uncertainty. Key Passenger and Financial Information Three months ended June 30 Six months ended June 30 (millions) 2025 2024 Change 1 2025 2024 Change 1 Passenger Activity % % Domestic 4.4 4.1 0.3 5.6 7.7 7.5 0.2 2.5 International 7.6 7.6 — — 15.0 15.1 (0.1) (1.0) Total 12.0 11.7 0.3 1.5 22.7 22.6 0.1 0.1 ($ millions) Total Revenues 520.7 485.3 35.4 7.3 1,008.1 953.8 54.3 5.7 EBITDA 2 260.9 240.5 20.4 8.4 477.8 460.0 17.8 3.9 EBITDA Margin 50.1 % 48.9 % 47.4 % 47.9 % Net Income 109.7 86.4 23.3 26.9 179.2 160.1 19.1 11.9 Free Cash Flow 2 53.8 39.9 13.9 34.8 184.6 160.6 24.0 14.9 1 Percentage calculations are based on detailed actual numbers (not rounded as presented). 2 Please refer to Non-GAAP Financial Measures at the end of this document for further details. Revenues for the second quarter were $520.7 million, an increase of 7.3%, year-to-date revenue was $1,008.1 million, an increase of 5.7%, compared to the same periods in 2024. The increase in the second quarter and year-to-date is primarily driven by rate and fee increases, aviation activity and a marginal increase in overall passenger traffic. Earnings before interest and financing costs, and amortization ("EBITDA") for the second quarter was $260.9 million, an increase of 8.4%, year-to-date EBITDA was $477.8 million, an increase of 3.9%, compared to the same periods of 2024. Higher revenues associated with the increase in aeronautical fees and Airport Improvement Fees were offset by the increase in operating costs (before amortization), reflecting investments in the year to support customer experience and to prepare the GTAA for medium to long-term growth in passenger volumes. Net income during the second quarter was $109.7 million, an increase of 26.9%, year-to-date net income was $179.2 million, an increase of 11.9%, compared to the same periods of 2024, driven by the increase in revenues being offset by the increase in expenses as mentioned above. Free cash flow for the second quarter was $53.8 million, an increase of 34.8% compared to the same period in 2024 primarily driven by higher cash flow from operations partially offset by lower interest income. Year-to-date free cash flow was $184.6 million, an increase of 14.9% compared to the same period in 2024, driven by higher cash flow from operations partially offset by lower receipt of funds under the Airport Critical Infrastructure Program ("ACIP"). Cash flows from operations are used to fund capital expenditures focused on improving facilities and enabling growth, while maintaining quality customer experience. The GTAA's June 30, 2025 financial results are discussed in more detail in the GTAA's Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis, each for the three and six-months ended June 30, 2025, which are available at and on SEDAR at Caution Regarding Forward-Looking Information This news release contains forward-looking information within the meaning of applicable securities laws. This forward-looking information is based on a variety of assumptions and is subject to risks and uncertainties. These statements reflect GTAA Management's current beliefs and are based on information currently available to GTAA Management. There is a risk that predictions, forecasts, conclusions and projections that constitute forward-looking information will not prove to be accurate, that the GTAA's assumptions may not be correct and that actual results may differ materially from such forward-looking information. Additional detailed information about these assumptions, risks and uncertainties is included in the GTAA's securities regulatory filings, including its most recent Annual Information Form and Management's Discussion and Analysis, which can be found on SEDAR at NON-GAAP FINANCIAL MEASURES Throughout this news release, there are references to the following performance measures which in Management's view are valuable in assessing the economic performance of the GTAA. While these financial measures are not defined by the International Accounting Standards Board and are referred to as non-GAAP measures which may not have any standardized meaning, they are common benchmarks in the industry, and are used by the GTAA in assessing its operating results, including operating profitability, cash flow and investment program. EBITDA EBITDA is earnings from operations before interest and financing costs, reversal or impairment of investment property, write-down of property and equipment, and amortization. EBITDA is a commonly used measure of a company's operating performance. This is used to evaluate the GTAA's performance without having to factor in financing and accounting decisions. Free Cash Flow Free Cash Flow ("FCF") is cash flows from operating activities per the consolidated statements of cash flows, and ACIP grants received less capital expenditures (property and equipment, investment property, and other) and interest and financing costs paid, net of interest income (excluding non-cash items). FCF is used to assess funds available for debt reduction or future investments within Toronto Pearson. About Toronto Pearson The Greater Toronto Airports Authority is the operator of Toronto Pearson International Airport, Canada's largest airport and a vital connector of people, businesses, and goods. Toronto Pearson has been named "Best Large Airport in North America serving more than 40 million passengers" seven times in the last eight years by Airports Council International, the global trade representative of the world's airports. Toronto Pearson was also recognized in 2025 as one of "Canada's Best Employers" by Forbes. For our corporate X channel, please visit @PearsonComms. For operational updates and passenger information, please visit @TorontoPearson/@AeroportPearson on X. You can also follow us on Facebook or Instagram.
